Epidermal growth factor receptor and variant III targeted immunotherapy.


Immunotherapeutic approaches to cancer have shown remarkable promise. A critical barrier to successfully executing such immune-mediated interventions is the selection of safe yet immunogenic targets. As patient deaths have occurred when tumor-associated antigens shared by normal tissue have been targeted by strong cellular immunotherapeutic platforms, route… (More)
DOI: 10.1093/neuonc/nou236